JWCTF (JW (Cayman) Therapeutics Co) Notes Receivable: $0.00 Mil (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
28 GF Score
Price $0.24
GF Value $0.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Notes Receivable?

JW (Cayman) Therapeutics Co JWCTF 28 Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review.

JW (Cayman) Therapeutics Co's Notes Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

JW (Cayman) Therapeutics Co Notes Receivable Related Terms

JW (Cayman) Therapeutics Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Notes Receivable Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JWCTF
28GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Notes Receivable of $0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on JW (Cayman) Therapeutics Co and its competitors.
Is JW (Cayman) Therapeutics Co's Notes Receivable too high?
JW (Cayman) Therapeutics Co's current Notes Receivable is $0.00 Mil. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Notes Receivable compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current Notes Receivable is $0.00 Mil. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score

Get the complete analysis for JWCTF

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$0.57
GF Value